Epicept - R.Cook / Lidopain, EP-1013 etc.

2010-01-19 21:59, Edited at: 2010-06-11 12:40

Frågeställning:

"I was searching for information regarding your deal with Endo, unsuccessfully. And trying to find out any progress made regarding Lidopain from Endo\\\'s end is futile. What is the status on this? I see that Endo is selling, with great success, Lidoderm that seams to be an exact copy of Lidopain. So what is really going on here? Also it would be nice to get an update and status on the following substances: Will there be any one of theese moving forward in the near future?

****EP-1013****
****Lidopain HM****
****Lidopain TV****
****EpiCept MP/DP****
****EP-2167****
****EP128504****
****EP192112****

Will there be any one of theese moving forward in the near future?

Regards, ####"

Robert Cook svarar

Thank you for your e-mail. LidoPain BP is in Phase II development but is not currently in a clinical trial. We have not pushed this drug into new clinical development because of resource constraints and our assessment that designing a successful trial to treat back pain is very difficult and risky. Endo is purported to be testing Lidoderm in back pain but we have no information to share in this regard. EpiCept licensed its patents for lidocaine as a topical treatment of back pain to Endo in 2004. Lidoderm is currently approved only for the treatment of post herpetic neuralgia.

Lidoerm is not an exact copy of LidoPain BP but is similar. Lidoderm contains 5% concentration of lidocaine while LidoPain contains a 20% concentration of lidocaine. The patches also have different modes of action.

As far as the other compounds you mentioned, we have no plans to develop further any of the pain compounds LidoPain HM, LidoPain TV, or EpiCept MP/DP. EP1013 has been licensed to GNI Ltd. where it is under active development. EP 2167, EP128504, and EP192112 are currently outlicensing candidates.

Bob Cook